UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


       Date of report (Date of earliest event reported): November 22, 2002




                         CURATIVE HEALTH SERVICES, INC.
             (Exact name of registrant as specified in its charter)


              Minnesota                    000-19370            41-1503914
   (State or other jurisdiction of        (Commission        (I.R.S. Employer
   incorporation or organization)        File Number)       Identification No.)


                                150 Motor Parkway
                         Hauppauge, New York 11788-5145
                    (Address of principal executive offices)


                                 (631) 232-7000
              (Registrant's telephone number, including area code)


                                 Not Applicable
          (Former name or former address, if changed since last report)







<PAGE>




Item 5.  Other Events and Regulation FD Disclosure

         On November 22, 2002, Curative Health Services, Inc. issued a press
release announcing it has completed its acquisition of OptCare Plus, Inc.
("OptCare") for approximately $10.5 million in cash. OptCare could also receive
additional proceeds depending upon the achievement of certain targets in
calendar year 2003. OptCare is a specialty pharmacy dispensing biological
medications such as Hemophilia clotting factors. OptCare's focus is on persons
affected by bleeding disorders. In addition, OptCare coordinates infusion
nursing and provides complete pharmacy services, clinical and reimbursement
support services to chronic disease communities. A copy of the press release is
attached as Exhibit 99.1, which is incorporated herein by reference under this
Item 5.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits

         (a) Financial Statements of Business Acquired

             Not required.

         (b) Pro Forma Financial Information

             Not required.

         (c) Exhibit

             Exhibit   Description of Exhibit
             -------   ----------------------

              99.1     Press Release  dated  November 22, 2002 relating to the
                       Company's completion of its acquisition of OptCare Plus,
                       Inc.  (subject to Item 5).



<PAGE>


Signature

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

                                             CURATIVE HEALTH SERVICES, INC.


Date:  November 25, 2002                     By:  /s/ Thomas Axmacher
                                                 --------------------
                                                      Thomas Axmacher
                                                      Chief Financial Officer



<PAGE>


                                                                 Exhibit 99.1
FOR IMMEDIATE RELEASE

Contact:                                             Richard Moyer
Scott Eckstein                                       Investor Relations
Investor Relations                                   Cameron Associates
Curative Health Services                             212-554-5466
631-232-7044                                         richard@cameronassoc.com
seckstein@curativehealth.com


                       CURATIVE HEALTH SERVICES COMPLETES
                           ACQUISITION OF OPTCARE PLUS

     Hauppauge,  New York - November 22, 2002 - Curative Health Services,  Inc.,
(Nasdaq: CURE), announced today that it has completed its acquisition of OptCare
Plus, Inc.  ("OptCare") for approximately  $10.5 million in cash.  OptCare could
also receive  additional  proceeds  depending  upon the  achievement  of certain
targets in calendar year 2003.

     OptCare is a specialty pharmacy dispensing  biological  medications such as
Hemophilia clotting factors.  OptCare's focus is on persons affected by bleeding
disorders.  In  addition,  OptCare  coordinates  infusion  nursing and  provides
complete  pharmacy  services,  clinical and  reimbursement  support  services to
chronic disease  communities.  OptCare's  service area primarily  focuses on the
populations of Virginia, Maryland and District of Columbia.

     "The combined  efforts of the teams at OptCare and our  Specialty  Pharmacy
unit  enabled us to close  this  transaction  ahead of  schedule,"  said  Joseph
Feshbach,  Curative's Chairman and Chief Executive Officer. "This prompt closing
is  enabling  an earlier  integration  of  OptCare  as a member of the  Curative
family.  Our  teams  will be  dedicated  to  ensuring  a smooth  and  successful
integration."

o    About Curative Health Services


     Curative Health Services  delivers superior clinical outcomes and unmatched
patient  satisfaction  for  patients  experiencing  serious  medical  conditions
through two unique business units.

     Curative's  Specialty  Pharmacy Services business unit provides services to
help  patients  manage the health  care  process,  and offers  related  pharmacy
products  to  patients  for  chronic  and  critical  disease  states,   such  as
Hemophilia.

Curative's Specialty Healthcare Services ("SHS") business unit is an industry
leader in chronic wound care management, consistently achieving an outcome
success rate of more than 80 percent. SHS provides a broad continuum of services
to health care providers through a nationwide network. This national network of
more than 100 hospital-based Wound Care Center(R) programs has offered
comprehensive treatment to over 300,000 patients, achieving more than a 95
percent patient satisfaction rate.
         For more information, visit www.curative.com
                                     ----------------

     This press release contains  forward-looking  statements within the meaning
of the Private  Securities  Litigation Reform Act of 1995. Such  forward-looking
statements  involve known and unknown  risks,  uncertainties  and other factors,
which may cause the actual results,  performance or achievements of the Company,
or  industry  results,  to be  materially  different  from any  future  results,
performance,  or  achievements  expressed  or  implied  by such  forward-looking
statements.  Factors  that might  cause such  differences  include,  but are not
limited to, the termination or non-renewal of a material number of contracts, an
inability  to  obtain  new  contracts,  changes  in the  government  regulations
relating to the Company's  Specialty  Healthcare  Services or Specialty Pharmacy
Services  business  units,  changes in the  regulations  governing  third  party
reimbursements for the Company's services,  manufacturing  shortages of products
sold by Curative's  Specialty  Pharmacy  Services  business  unit, and the other
risks and  uncertainties  detailed in the Company's  filings with the Securities
and Exchange  Commission.  Readers of this release are referred to the Company's
Quarterly  Report on Form 10Q for the quarter  ended  September  30,  2002,  for
further discussion of these and other factors that could affect future results.

   Editors Note: This release is also available on the Internet over the World
                      Wide Web at: http://www.curative.com
                                   -----------------------

                                       ###
[{"type": "8-K", "sequence": "1", "filename": "optcare112202.txt", "description": "OPTCARE PLUS PRESS RELEASE 11.22.02", "secsgml_size_bytes": 7711}]
{"company-data": {"conformed-name": "CURATIVE HEALTH SERVICES INC", "cik": "0000874212", "assigned-sic": "8093", "irs-number": "411503914", "state-of-incorporation": "MN", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19370", "film-number": "02838743"}, "business-address": {"street1": "150 MOTOR PARKWAY", "city": "HAUPPAUGE", "state": "NY", "zip": "11788-5145", "phone": "5162327000"}, "mail-address": {"street1": "150 MOTOR PARKWAY", "city": "HAUPPAUGE", "state": "NY", "zip": "117885145"}, "former-company": {"former-conformed-name": "CURATIVE TECHNOLOGIES INC /MN", "date-changed": "19930328"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of report (Date of earliest event reported): November 22, 2002

                         CURATIVE HEALTH SERVICES, INC.
             (Exact name of registrant as specified in its charter)

              Minnesota                    000-19370            41-1503914
   (State or other jurisdiction of        (Commission        (I.R.S. Employer
   incorporation or organization)        File Number)       Identification No.)

                                150 Motor Parkway
                         Hauppauge, New York 11788-5145
                    (Address of principal executive offices)

                                 (631) 232-7000
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)
Item 5.  Other Events and Regulation FD Disclosure

         On November 22, 2002, Curative Health Services, Inc. issued a press
release announcing it has completed its acquisition of OptCare Plus, Inc.
("OptCare") for approximately $10.5 million in cash. OptCare could also receive
additional proceeds depending upon the achievement of certain targets in
calendar year 2003. OptCare is a specialty pharmacy dispensing biological
medications such as Hemophilia clotting factors. OptCare's focus is on persons
affected by bleeding disorders. In addition, OptCare coordinates infusion
nursing and provides complete pharmacy services, clinical and reimbursement
support services to chronic disease communities. A copy of the press release is
attached as Exhibit 99.1, which is incorporated herein by reference under this
Item 5.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits

         (a) Financial Statements of Business Acquired

             Not required.

         (b) Pro Forma Financial Information

             Not required.

         (c) Exhibit

             Exhibit   Description of Exhibit
             -------   ----------------------

              99.1     Press Release  dated  November 22, 2002 relating to the
                       Company's completion of its acquisition of OptCare Plus,
                       Inc.  (subject to Item 5).
Signature

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

                                             CURATIVE HEALTH SERVICES, INC.

Date:  November 25, 2002                     By:  /s/ Thomas Axmacher
                                                 --------------------
                                                      Thomas Axmacher
                                                      Chief Financial Officer
Exhibit 99.1
FOR IMMEDIATE RELEASE

Contact:                                             Richard Moyer
Scott Eckstein                                       Investor Relations
Investor Relations                                   Cameron Associates
Curative Health Services                             212-554-5466
631-232-7044                                         richard@cameronassoc.com
seckstein@curativehealth.com

                       CURATIVE HEALTH SERVICES COMPLETES
                           ACQUISITION OF OPTCARE PLUS

     Hauppauge,  New York - November 22, 2002 - Curative Health Services,  Inc.,
(Nasdaq: CURE), announced today that it has completed its acquisition of OptCare
Plus, Inc.  ("OptCare") for approximately  $10.5 million in cash.  OptCare could
also receive  additional  proceeds  depending  upon the  achievement  of certain
targets in calendar year 2003.

     OptCare is a specialty pharmacy dispensing  biological  medications such as
Hemophilia clotting factors.  OptCare's focus is on persons affected by bleeding
disorders.  In  addition,  OptCare  coordinates  infusion  nursing and  provides
complete  pharmacy  services,  clinical and  reimbursement  support  services to
chronic disease  communities.  OptCare's  service area primarily  focuses on the
populations of Virginia, Maryland and District of Columbia.

     "The combined  efforts of the teams at OptCare and our  Specialty  Pharmacy
unit  enabled us to close  this  transaction  ahead of  schedule,"  said  Joseph
Feshbach,  Curative's Chairman and Chief Executive Officer. "This prompt closing
is  enabling  an earlier  integration  of  OptCare  as a member of the  Curative
family.  Our  teams  will be  dedicated  to  ensuring  a smooth  and  successful
integration."

o    About Curative Health Services

     Curative Health Services  delivers superior clinical outcomes and unmatched
patient  satisfaction  for  patients  experiencing  serious  medical  conditions
through two unique business units.

     Curative's  Specialty  Pharmacy Services business unit provides services to
help  patients  manage the health  care  process,  and offers  related  pharmacy
products  to  patients  for  chronic  and  critical  disease  states,   such  as
Hemophilia.

Curative's Specialty Healthcare Services ("SHS") business unit is an industry
leader in chronic wound care management, consistently achieving an outcome
success rate of more than 80 percent. SHS provides a broad continuum of services
to health care providers through a nationwide network. This national network of
more than 100 hospital-based Wound Care Center(R) programs has offered
comprehensive treatment to over 300,000 patients, achieving more than a 95
percent patient satisfaction rate.
         For more information, visit www.curative.com
                                     ----------------

     This press release contains  forward-looking  statements within the meaning
of the Private  Securities  Litigation Reform Act of 1995. Such  forward-looking
statements  involve known and unknown  risks,  uncertainties  and other factors,
which may cause the actual results,  performance or achievements of the Company,
or  industry  results,  to be  materially  different  from any  future  results,
performance,  or  achievements  expressed  or  implied  by such  forward-looking
statements.  Factors  that might  cause such  differences  include,  but are not
limited to, the termination or non-renewal of a material number of contracts, an
inability  to  obtain  new  contracts,  changes  in the  government  regulations
relating to the Company's  Specialty  Healthcare  Services or Specialty Pharmacy
Services  business  units,  changes in the  regulations  governing  third  party
reimbursements for the Company's services,  manufacturing  shortages of products
sold by Curative's  Specialty  Pharmacy  Services  business  unit, and the other
risks and  uncertainties  detailed in the Company's  filings with the Securities
and Exchange  Commission.  Readers of this release are referred to the Company's
Quarterly  Report on Form 10Q for the quarter  ended  September  30,  2002,  for
further discussion of these and other factors that could affect future results.

   Editors Note: This release is also available on the Internet over the World
                      Wide Web at: http://www.curative.com
                                   -----------------------

                                       ###